ANI Pharmaceuticals has disclosed the outcomes of its NEW DAY trial, assessing Iluvien 0.19mg, in people with diabetic macular oedema.

The COVID-19 pandemic accelerated biological brain aging in older adults by an average of 5.5 months over less than three ...